From May 2006 to December 2007 in Warsaw Hospital for Infectious Diseases one hundred and eight patients chronically infected HBV were treated with lamivudine. Among them 46 (42.5%) were HBeAg (+) and 62 (57.5%) HBeAg (-). HBV DNA levels were analysed in weeks 24, 48 and 72 of therapy using Real Time HBV PCR (Abbott) with a limit of detection of 28 copies/ml. Complete response for treatment was defined as HBV VL of less than 10(2) copies/ml (group A). Partial response was defined as HBV VL ranging from 10(2) to 10(5) copies/ml (group B), and treatment failure was determined by HBV VL above 10(5) copies/ml (group C). Presented results confirmed better response to lamivudine treatment in patients HBeAg (-) than HBeAg (+).